Editas Medicine Q2 net loss narrows and beats estimates

Editas Medicine

05/08/2026 21:11

Overview
US gene editing firm's Q2 net loss narrowed and beat analyst expectations
Collaboration and other R&D revenue more than tripled yr/yr to $11.9 mln
Company completed $125 mln equity financing, cash runway into H2 2028

Outlook
Editas expects to submit a CTN in Australia for EDIT-401 this month
Company plans to provide a data update on EDIT-401 in Q1 2027
Editas expects existing cash to fund operations into the second half of 2028

Result Drivers
DEFERRED REVENUE RECOGNITION - Revenue growth was mainly due to recognition of deferred revenue after expiration of certain rights under BMS collaboration
HIGHER R&D SPENDING - Research and development expenses rose due to increased external costs for ongoing EDIT-401 preclinical work
LOWER G&A COSTS - General and administrative expenses fell, reflecting workforce reductions and discontinuation of a prior clinical program
RESTRUCTURING BENEFIT - Restructuring and impairment charges shifted to a benefit due to favorable adjustments to prior estimated contract costs

Company press release: ID:nGNX9GRQcp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration and other research and development revenue
 
$11.90 mln
 
Q2 Loss Per Share
 
$0.15
 
Q2 Net Loss
Beat
$18.23 mln
$27.01 mln (10 Analysts)
Q2 Operating Expenses
 
$30.44 mln
 
Q2 Operating Income
 
-$18.55 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Editas Medicine, Inc. is $5.00, about 80.5% above its August 4 closing price of $2.77

Reuters Recommended Reads
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 5 - Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Aug 5 - Entrada Therapeutics Q2 net loss narrows on lower costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)